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PROTEOLYTIC ACTIVITY IN DERMATOSES: PRELIMINARY
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FRANK E. CORMIA, M.D., JOHN W. DOUGHERTY, Ml). AND
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There is increasing evidence that inflammation is mediated by the breakdown
of tissue protein (1). Recently Shelley and Arthur (2) have shown that itching
can be produced by a similar mechanism. In this paper experiments which amplify
and tend to confirm this concept will be documented.
In recent studies Ungar (1) has related the process of inflammation to the ef-
fects of proteolytic enzymes liberated following tissue injury. This sequence of
events will be shown to be equally applicable to itching. In chart 1 the mecha-
nisms in the development of inflammation have been simplified so that events
from the initial tissue injury to the final reaction can be visualized. While Un-
gar's concept is based mainly on the fibrinolytic mechanism in the blood, it is
becoming increasingly evident that proteases, regardless of their origin, may
have an essentially similar action on tissue protein. Proteolytic enzymes of the
endopeptidase type have been identified not only in the blood, but also in
leucocytes (3), skin (4), and in various tissues as cathepsins (5). Following the
initial tissue injury, various kinases are liberated. These include bacterial
kinases (6), cytokinase (7) and serokinase (8). These kinases do not act on
enzyme precursors, but on a proactivator in tissue (9). This in turn is converted
into an activator which acts on the enzyme precursor to form the proteolytic
enzyme. When the protein molecule is split by a protease (proteolytic enzyme),
histamine which has been bound to the tissue is released (10), and complex poly-
peptides are liberated (11). These substances may be the mediators of the end
reaction of inflammation and/or itching.
In the fibrinolytic system studied by Ungar, the conversion of the proenzyme
(plasminogen or profibrinolysin) to the proteolytic enzyme fibrinolysin can be
prevented by heparin (8), and activated fibrinolysin can be blocked by such
chemicals as sodium salicylate (12). The inactivation of fibrinolysin by the in-
hibitor, antifibrinolysin, can be accelerated by ACTH and the corticosteroids
(13). Conversely, this reaction may be inhibited by the growth hormone of the
pituitary and desoxycorticosterone. Some of these mechanisms apparently do not
play a major role in inflammation of the skin. For example, the salicylates do
not have a noticable ameliorating effect on dermatitis, while the effect of the
corticosteroids is well-known.
Until recently, it was thought that itching was mediated largely by hista-
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CHART 1
mine. Severe itching occurs commonly in clinically normal skin; conversely,
itching from histamine is always accompanied by a visible reaction. This dis-
crepancy led Shelley and Arthur to investigate itching produced by cowhage
(2). A proteolytic enzyme was extracted from the cowhage spicules. Injections
of minute amounts of this enzyme produced itching without any visible reaction.
They then found that various proteolytic enzymes of the endopeptidase series
produced itching on injection. Enzymes studied included that isolated from
cowhage, papain, bromelin, ficin, fungal and bacterial proteinases. Effective ani-
mal proteinases were trypsin, chymotrypsin and fibrinolysin (plasmin). It would
appear that the proteases native to human tissue are the primary instigators of
itch. It is true that the proteases are potent histamine liberators (14). Following
an intradermal injection of a protease, however, itching frequently occurs prior
to the appearance of the triple response.
MATERIALS AND METHODS
The substances used in the present investigation included crystalline trypsin, lyophilized
fibrinolysin and profibrinolysin, bovine antifibrinolysin, ficin, papain, moccasin snake
venom, and relatively purified streptokinase.* Epidermal protease was prepared from skin
obtained from surgically removed breasts. Epidermis was obtained by the stretch method
of Van Scott (15), the protease prepared after the method of Beloff and Peters (4), lyophil-
ized, made into a 1:1,000 solution, and sterilized by passage through a Seitz filter. Hista-
mine solutions were freshly prepared from powdered histamine phosphate.
Initially, the proteolytic enzymes were injected intradermally in normal subjects. When
the material was found to be safe for injection and when the general reaction patterns had
been determined, patients with itching or dermatitis were also tested. Since these materials
are proteins, the possibility of developing sensitization had to be considered. Of the en-
* Bovine antifibrinolysin was obtained from Dr. George Ungar, Director of Pharma-
cology, 15. S. Vitamin Corp., Yonkers, New York. Streptokinase was supplied by Dr. J.
M. Ruegsegger, Lederle Laboratories, Pearl River, New York. Plasminogen was supplied
by Dr. E. E. Clifton, N. Y. Lyophilized human fibrinolysin was obtained from Dr. D. S.
Brashear, Sharp and Dohme, West Point, Pa. Crystalline trypsin, ficin and papain were
products of worthington Biochemical Company, Freehold, N. J.
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zymes tested, crystalline trypsin was the only proteolytic enzyme which could be injected
over a long period of time without danger of developing sensitization. Severe tuberculin-
type local reactions to fibrinolysin were encountered in one subject. Because of the fre-
quency of previous streptococcal infections, reactions to streptokinase were anticipated.
Such reactions were found, and were moderately severe in one subject.
Solutions for injection were freshly prepared, since proteolytic activity in solutions is
lost rapidly and is absent after 24 hours. The enzymes were dissolved in a specially pre-
pared solution,* shown previously not to produce itching or burning on intradermal in-
jection. In general, 1:1,000 solutions were used, although at times dilutions as great as
1:1,000,000 were made. A 0.25 ml. syringe was used and the amount of solution injected
was kept constant at 0.02 ml. Twenty-seven gauge needles were used. Individual test ma-
terials varied in activity when received. For example, itching could not be produced with
one lot of streptokinase. The concentration of lyophilized enzyme producing itching was
greater than that of crystalline preparations. Most injections were given by one individual
in order to maintain a relatively constant technic.
OBSERVATIONS
1. Experiments on inflammation
a. Intradermal injection of crystalline trypsin in uninvolved skin tended to
aggrevate existing dermatoses. Such aggravation was observed in dermatophy-
tosis, atopic dermatitis, erythroderma, urticaria, and pemphigus. The aggra-
vating effect of trypsin and fibrinolysin in these patients has not been constant.
b. The effect of trypsin on the triple response. Dilatation of the minute blood
vessels (erythematous flare) was produced by stroking the skin of the forearm
and the back of several normal individuals. After the whealing had subsided,
but when the secondary histamine flare was prominent, trypsin \vas injected
adjacent to the site of stroking. After approximately twenty minutes, the erythem-
atous reactiou had reappeared over both sites of previous stroking (Figure 1.)
The mechanism of this action has not yet been determined. It may be due to
the secondary release of histamine or the activation of another proteolytie
enzyme system.
2. Experiments on itching
a. Try psin. Solutions of crystalline trypsin were injected intradermally in 10
normal subjects and in the uninvolved skin of 15 patients with pruritus or der-
matitis. Concentrations varied from 1:1,000 to 1:300,000. Itching could be pro-
duced invariably with a 1:1,000 solution; many subjects reacted to dilutions of
1:50,000 to 1:80,000. Reactions to dilutions greater than 1:100,000 were not
seen in normal subjects. The sensation experienced varied in character and in-
cluded pricking, stinging, slight to severe itching, and burning. The average
time of onset of itching after injection was 16 seconds, with limits of S seconds
to 13' minutes. The sensation persisted from 1 to 7 minutes with an average of





Distilled water to 1,000 ml.
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FIG. 1. Reappearance of erythematous flare following intradermal injection of tryp-
sin.
dermatitis than in controls. A secondary histamine flare was a usual but not in-
variable sequel following injection. At times it was noted before onset of itching,
at other times the converse was true. Histamine flares varied in size from 2 to
5 cm. bnt were smaller and less erythematous than those produced by 1:1,000
solution of histamine (16).
Itch thresholds were estimated in 5 normal subjects for 5 consecutive days.
The thresholds were determined by intradermal injections of increasing dilu-
tions of trypsin. The thresholds varied from 1 :20,000 to 1:80,000 in two, 1:40,000
to 1:80,000 in two, and 1:60,000 to 1:80,000 in one.
b. Other Proteases. Fibrinolysin was injected intradermally in 6 controls and
in the nninvolved skin of 2 patients with severe dermatitis. The reactions were
similar to those obtained with trypsin in normal subjects. Moderate itching was
produced with a 1:1,000 solution, while in the 2 patients with itching, a 1:1,000
solution produced no reaction in one patient and slight burning in the other.
The average time of onset of itching was 19 seconds after injection with ex-
tremes from 3 seconds to 1 minute. The itching lasted from 13 to 7 minntes,
with an average of 3 minutes. Profibrinolysin in a dilution of 1:1,000 was in-
jected in 3 normal subjects. Sensations varied from slight to moderate itching to
moderate burning, even in the same subject. The average time of onset of itch-
i'.
4-
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ing was 21 seconds with extremes of 10 to 35 seconds. Mild secondary histamine
flares were again observed. Ficin was used in three normal subjects. A dilution
of 1:100,000 gave little or no reaction, while 1:1,000 produced a severe burning
itch at 5 seconds and lasted 5 minutes. A 1:1,000 solution of papain produced
mild itching in 1 normal subject and no reaction in 2 others. A fourth control
tested with a 1:1,000 solution developed mild itching in 1 minute, persisting for
3 minutes. Moccasin snake venom, reputedly a potent proteolytic enzyme, failed
to produce itching in 2 normal subjects when injected in a 1:5,000 dilution.
Epidermal protease was injected intradermally in three control subjects. All
developed slight to moderate itching, depending upon the amount injected.
Itching occurred in 12 to 75 seconds and lasted 2 to 10 minutes.
c. Streptokinase. Purified streptokinase was injected intradermally in 3 normal
subjects. Thirty units were injected in all three, while one was injected with
300 units as well. With 30 units, itching was experienced at 3, 5, 7 minutes, re-
spectively. Delayed reactions were not seen in one individual. In the second,
injected with 300 units, an elevated erythematous reaction (7.5 cm.) developed
during 48 hours. The third subject had a severe reaction following the injection
of 30 units. This consisted of an area of swelling and redness some 5 by 10 cm.
in size developing over a period of 12 to 24 hours. It was accompanied by severe
pain and general malaise and persisted for 2 days.
d. Differentiation of reactions to histamine and trypsin. The local itch response
to histamine was exhausted in 3 control subjects by 5 consecutive intradermal
injections of 1: 1,000 solution of histamine in a single site, as previously reported
(16). A 1:1,000 solution of trypsin was then injected at the same site. One sub-
ject experienced slight itch, a second mild burning pain and a third slight pain.
e. Scattered itching after injections of trypsin, fibrinolysin, and streptokinase.
Four of ten normal subjects injected with trypsin, and one of seven with fibrinoly-
sin, developed scattered itching over the body after 20 minutes. The itching
lasted from one to three hours depending on the amount of protease injected.
The itching tended to recur at the same sites on subsequent injections. All of
three controls injected with streptokinase had similar reactions, but the dura-
tion was increased from three to eight hours.
f. Patients with itching with or without dermatitis tend to react to locally injected
proteolytic enzymes in a manner different than normal subjects. In some patients
with severe extensive pruritus, itching could not be produced by local injection
of proteolytic enzymes or by histamine. In other patients with severe extensive
chronic pruritus, the amount of proteolytic enzyme which elicited itching was
larger than that necessary in normal subjects. Moreover, the appearance of the
itching was apt to be delayed, sometimes for as long as two minutes after in-
jection. The explanation for these apparent discrepancies is not known. Patients
with localized pruritus, for example localized neurodermatitis, ordinarily devel-
oped itching to smaller amounts of injected proteolytic enzymes in involved as
compared with normal skin sites. If the pruritus was of long standing, injections
of proteolytic enzymes into involved sites or distal areas of normal skin fre-
quently caused an exacerbation of itching throughout the entire involved area.
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DISCUSSION
Data has been presented which suggests that various types of dermatitis may
be aggravated by injection of proteolytic enzymes.
The present findings confirm the report of Shelley and Arthur (17) that itch-
ing may be mediated by proteolytic enzymes. The experiments suggest that the
sequence of events leading to itching is identical with that suggested by Ungar
in inflammation. If histamine is injected intradermally, itching occurs in 1 to 3
seconds, with trypsin, the interval averages 16 seconds, with fibrinolysin 19 sec-
onds, with profibrinolysin 21 seconds, and with streptokinase 3 to 7 minutes.
These findings indicate roughly the time necessary for the completion of the vari-
ous phases of the proteolytic cycle. Apparently profibrinolysin is converted to
fibrinolysin almost instantly, since the time interval between injection and onset
of itching is approximately the same with both substances. Considerable varia-
tion in the itch response to the intradermal injection of a protease occurs in
normal subjects and in patients with pruritus and dermatitis. This applies to
specific concentration of enzymes, time of onset of response, and character of
sensation. It may be due to several factors, 1. potency of injected material,
2. altered predisposition of certain areas to itch, and 3. the precise site of injected
material. Other factors such as the emotional status of the individual and the
availability of protease inhibitors have not yet been evaluated. The prediliction
of scattered itching to occur at the same sites following the injection of a pro-
teolytic enzyme has been noted in several subjects. When a chronic pruritogenic
stimulus is present, these predisposed sites may determine to a large extent the
location of pruritus in patients. The location of an intradermal injection of a
protease, particularly when the amount injected is small, may modify greatly the
itch response. This variability in response may be due to the local distribution of
terminal fibers and to the potency of the injected protease. The response to
histamine has been more constant, due to more uniform potency, and to the
fact that a large injection (0.05 ml.) exerts its effects on a larger number of pain
fibers.
The sensory response to an intradermal injection of protease is variable in
character. Pure itch may be experienced. The itch may be combined with burn-
ing. Stinging sensations may be noted, or mild pricking pains may be experienced.
This finding differs from that of Arthur and Shelley (17), who noted that the in-
troduction of a cowhage spicule into the skin resulted in a pure itch. The differ-
ence in response may be due to the increase in proteolysis which follows the intra-
dermal injection of a larger amount of protease.
Formerly, it was thought that itching was mediated largely by histamine.
Nevertheless, itching may occur without visible reaction, and histamine injected
intradermally does not produce itching in the absence of this reaction. In the
present experiments, itching following the injection of a protease often preceded
the visible histamine response. When the itch response to histamine in a local
cutaneous site was exhausted by repeated inj ections of histamine, itching or
burning could still be produced by local injection of a proteolytic enzyme.
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The tendency of itching to be self-perpetuating may be augmented by various
secondary factors, which are summarized in chart 2. In this chart, some of the
mechanisms which initiate the release of proteolytic enzymes have been listed.
It is probable that increased proteolytic activity is present also in uremia,
lymphoblastoma, and emotional states. Ungar has shown recently that pro-
teolytic activity is present in peripheral nerves (18). Elevated serum inhibitor
levels have been reported in some of the lymphomas (19) and in certain psychoses
(20). The question arises as to why some patients with these syndromes itch and
others do not. It is probable that release of proteolytic enzymes is followed by
variable patterns of enzyme reactivity in individual subjects. The development
of prolonged itching in scattered districts following intradermal injection of rela-
tively small amounts of a proteolytic enzyme suggests that itching, once initiated,
tends to perpetuate itself for variable lengths of time. In patients who develop
itching, there may be either a sustained release of enzyme through continued
activation or an inadequate inhibitor mechanism. At any event, itching with or
without dermatitis leads to scratching, superimposed dermatitis and infection
Scratching presumably releases epidermal cathepsins, superimposed dermatitis
may be associated with increased fibrinolytic activity, and secondary infection
results in the liberation of bacterial kinases. Leucoprotease released by the de-
struction of leucocytes also may be important; the role of leucoprotease in the
production of itching is now being investigated. It is probable that this produces
further tissue injury and more release of proteolytic enzymes. Thus, the cycle
may be perpetuated, even when the precipitating cause has been removed.
CHART 2
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CONCLUSIONS
1. The intradermal injection of fibrinolysin or crystalline trypsin frequently
aggravated various types of dermatitis, urticaria and pemphigus.
2. The intradermal injection of trypsin aggravated the preexisting triple re-
sponse of Lewis and reactivated a quiescent one.
3. Itching was produced regularly by the intradermal injection of strepto-
kinase, profibrinolysin, fibrinolysin, trypsin, ficin and papain, thus confirming
the studies of Shelley and Arthur. Itching could not he produced with moccasin
snake venom.
4. Itching was produced by the intradermal injection of epidermal protease.
5. The intradermal injection of proteolytic enzymes nearly always produced
a secondary triple response, but this was less severe than that developing after
the injection of a comparable amount of histamine.
6. The time-sequence of the development of itching following intradermal
injections of streptokinase, profibrinolysin, fibrinolysin and histamine indicates
that the mechanisms involved in pruritus are similar to those of inflammation.
7. The utilization of trypsin for the determination of threshold itch is less re-
liable than when histamine is used.
8. Itching scattered over the body was often produced by the injection of
streptokinase, fibrinolysin and trypsin.
9. Following the exhaustion of the local itch response to histamine, itching
could still be produced by a local injection of 1:1,000 solution of trypsin.
10. The itch response to proteolytic enzymes in patients with dermatitis varied
greatly from that in normal controls. Patients with localized pruritus tended to
be hypersensitive, while those with extensive severe itching were usually hypo-
sensitive or non-reactive.
The authors wish to express their thanks to Dr. George Ungar for his many
suggestions, and for his help in the preparation of epidermal protease.
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